PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026International Journal of Infectious Diseases0 citationsOpen Access

Efficacy and Safety of Albuvirtide Intensification for Low-Level Viremia in People Living with HIV-1: A Retrospective Pilot Study

CZChunjuan ZhangSQShu QianPLPing Li

Key Points

  • This study aims to assess the efficacy and safety of albuvirtide (ABT) intensification for managing low-level HIV-1 viremia.
  • Retrospective analysis of patients living with HIV-1
  • Assessment of viral load and CD4+/CD8+ T-cell counts over 28 weeks
  • Focus on high-risk individuals for intensified treatment
  • Viral suppression achieved in 85.2% of patients by week 28
  • Significant increase in CD4+ T-cell counts observed
  • No expansion of CD8+ T-cells noted
  • Marked improvement in CD4/CD8 ratio following treatment

Abstract

ABT intensification effectively suppresses HIV-1 low-level viremia. Viral suppression reached 85.2% by week 28 in high-risk patients. CD4+ T-cell counts increased significantly without CD8+ expansion. The CD4/CD8 ratio improved markedly following ABT treatment.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69cd79e15652765b073a6c82https://doi.org/10.1016/j.ijid.2026.108671
Ask AI
Helpful
Bookmark
Share
View Full Paper